Use Misoprostol to Optimize Prevention of Cervical Cancer
Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial
University of Alabama at Birmingham
420 participants
Feb 25, 2025
INTERVENTIONAL
Conditions
Summary
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.
Eligibility
Inclusion Criteria2
- Diagnosis of Type 3 TZ confirmed on exam prior to randomization
- Age 25 years or older
Exclusion Criteria5
- With Type 1 or 2 TZ prior to randomization
- Currently pregnant
- History of hysterectomy
- Any cancerous lesions
- Active cervicitis
Interventions
Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06669533